Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration [Y...
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Broad GCase elevation achieved in NHPs, while significantly detargeting the liver compared with AAV9, with no clinical pathology, immunogenicity, or histopathology findings, including in DRGs Wholly owned program on track for clinical entry in the first half of 2025 THOUSAND OAKS, Calif. May 10, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new preclinical data that demonstrate the potential of its next-generation intravenously (IV) administered gene therapy candidate, CAP-003, to safely and effectively treat Parkinson's disease (PD) associated with GBA mutations (PD-GBA). Collectively, the findings strongly support the best-in-class profile of CAP-003 and Capsida's plans to advance the therapy into clinical trials in the first half of 2025. Mutations in GBA, the gene expressing the GCase enzyme, are the most common genetic risk factor for PD. Other treatments for PD-GBA have been limited by their inability to cross the blood-brain barrier and supplem
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Swiss biotech ecosystem recuperates from global financial instability [Yahoo! Finance]Yahoo! Finance
- Cathie Wood Has Been Steadily Selling Shares of This Growth Stock. Should You? [Yahoo! Finance]Yahoo! Finance
- Genome Editing Technologies market is projected to grow at a CAGR of 17.6% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
CRSP
Earnings
- 5/9/24 - Beat
CRSP
Sec Filings
- 6/3/24 - Form 8-K
- 5/31/24 - Form 4
- 5/31/24 - Form 4
- CRSP's page on the SEC website